Liontrust Global Smaller Companies Fund

The Liontrust Global Smaller Companies Fund returned 5.4% over the quarter, versus the MSCI ACWI Small Cap Index and IA Global sector respective returns of 1.4% and 4.1% (both comparator benchmarks)*.

Global financial markets were generally higher in Q1, marking a second quarter of modest recovery. Investor sentiment improved throughout January and February but was disturbed in March when some regional US banks experienced deposit flight and were forced to realise losses on their long duration held-to-maturity bond portfolios. Problems at Credit Suisse added to the jitters, but policymakers on both sides of the Atlantic were quick to provide support and worries of a systemic issue subsided. The Fed has continued to raise rates albeit less aggressively and it does seem we are close to a cycle peak after a year of tightening. US growth stocks outperformed in March on expectations that interest rate rises would be less than feared. Leading indicators of US inflation continue to decline, helped by lower oil and gas prices, but it still persists, especially in the services sector. Central banks in Europe also continued to raise rates.

On balance, the banking crisis has made it a little more difficult for the US economy to avoid a recession by tightening conditions in the sector. Consumers are realising that bank deposits are not risk free and they must compete with the higher rates paid by money market funds. This will likely raise the cost of funds for banks and so ultimately increase the cost of loans. Second, the regional banks are likely to be more cautious in lending, and commercial real estate is probably the area where any slowdown in lending by these regional banks will show first. We are monitoring this area for indications of stress. Our global and international equity funds are underweight the financial sector, particularly traditional banks where we view the risk-reward skew of potential returns against us.

Economic prospects in China are brightening. The post-Covid reopening continues apace, although geopolitical tensions are rising versus the US and its allies. Generally, politics continues to be an important determinant of what the world will likely look like in five years. But since President Xi was elected for a fourth term, pragmatism has taken priority over dogmatism, which will likely boost China’s economy and have global ramifications.

Monetary policies remain a key focus for investors.  Conversely, our attention is increasingly drawn to more analysis of companies’ fundamentals. Indeed, changes in our portfolios over the last quarter have been more stock- than macro-driven. Drawing themes from the companies that we are investing in – early-stage cyclicals are showing great promise, helped by falling energy prices and receding supply chain issues, and structural growth companies are looking more attractive against a more dovish array of central banks.

There are still uncertainties, and it does feel like risks have increased in recent weeks with the US banking crisis perhaps pressing the brakes a little too hard on the economy at a time of tightening. But investors with a long-term view can capitalise on this uncertainty, selecting those stocks for which the risk-rewards are favourable.

From a stock perspective, positive contributions came from Evoqua Water Technologies (water technology provider focused on helping our customers solve the world's toughest water challenges through innovative products, services, and solutions based on technology and expertise), Silicon Laboratories (maker of silicon, software and solutions for a more connected world), Shutterstock (provider of stock photography, stock footage, stock music, and editing tools) and Topicus.com (provider of vertical market software and vertical market platforms to clients in a select group of public and private sector markets).

On the other side of the ledger, notable detractors were Acadia Healthcare (an American provider of behavioural healthcare services), Box Inc. (developer and marketer of cloud-based content management, collaboration, and file sharing tools for businesses) and LivaNova (a global medical device company creating neuromodulation devices and cardiopulmonary products to improve the lives of patients around the world).

Discrete years' performance (%)**, to previous quarter-end:

*Source: FE Analytics as at 31.03.23

**Source: FE Analytics as at 31.03.23. Quartiles generated on 06.04.23

KEY RISKS

Past performance is not a guide to future performance. The value of an investment and the income generated from it can fall as well as rise and is not guaranteed. You may get back less than you originally invested.

The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term.

The portfolio is invested in smaller companies - these stocks may be less liquid and the price swings greater than those in, for example, larger companies. Investment in the Fund involves foreign currencies and may be subject to fluctuations in value due to movements in exchange rates. The Fund may invest in emerging markets/soft currencies or in financial derivative instruments, both of which may have the effect of increasing volatility. The Fund holds a concentrated portfolio of stocks, if the price of one of these stocks should move significantly, this may have a notable effect on the value of the portfolio.

DISCLAIMER

This is a marketing communication. Before making an investment, you should read the relevant Prospectus and the Key Investor Information Document (KIID), which provide full product details including investment charges and risks. These documents can be obtained, free of charge, from www.liontrust.co.uk or direct from Liontrust. Always research your own investments. If you are not a professional investor please consult a regulated financial adviser regarding the suitability of such an investment for you and your personal circumstances.

This should not be construed as advice for investment in any product or security mentioned, an offer to buy or sell units/shares of Funds mentioned, or a solicitation to purchase securities in any company or investment product. Examples of stocks are provided for general information only to demonstrate our investment philosophy. The investment being promoted is for units in a fund, not directly in the underlying assets. It contains information and analysis that is believed to be accurate at the time of publication, but is subject to change without notice. Whilst care has been taken in compiling the content of this document, no representation or warranty, express or implied, is made by Liontrust as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified. It should not be copied, forwarded, reproduced, divulged or otherwise distributed in any form whether by way of fax, email, oral or otherwise, in whole or in part without the express and prior written consent of Liontrust.